Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 6:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 5,229 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control/Placebo group Clear all

Conditions: Alzheimer's Disease
Interventions: Coconut Oil Beverage, Placebo Beverage; Drug · Other
Lead sponsor: University of South Florida; Other
Eligibility: 55 Years to 90 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Joint Discomfort, Joint Pain, Stiffness, Function, Joint Pain, Hot Flashes, Hot Flash, Night Sweats, Vasomotor Symptoms
Interventions: JDS-HF3.0, Placebo; Dietary Supplement · Other
Lead sponsor: Bonafide Health; Industry
Eligibility: 50 Years to 70 Years · Female only
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Harrison, New York

Conditions: Opioid Consumption, Postoperative
Interventions: Suzetrigine, Standard Care (in control arm); Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: La Jolla, California

Conditions: HIV Infections
Interventions: env (A,B,C,A/E)/gag (C) DNA Vaccine, gp120 (A,B,C,A/E) Protein Vaccine, Placebo, GLA-SE adjuvant; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 6
States / cities: Birmingham, Alabama • Decatur, Georgia • Boston, Massachusetts + 3 more

Conditions: Hearing Loss
Interventions: Attention to Variability (ATV), Placebo; Behavioral · Other
Lead sponsor: Harvard University; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: ASD, Autism Spectrum Disorder, Autism, Depression - Major Depressive Disorder, MDD
Interventions: Transcranial Magnetic Stimulation, Transcranial Magnetic Stimulation Sham; Procedure
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 13 Years to 26 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Scoliosis, Pain
Interventions: Methadone, Normal Saline, Morphine; Drug · Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 10 Years to 18 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Asthma
Interventions: Mepolizumab, Placebo, OCS (prednisone/prednisolone); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 8
States / cities: Long Beach, California • Denver, Colorado • New Haven, Connecticut + 5 more

Conditions: Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Skin Neoplasms, Skin Diseases, Neoplasms, Basal Cell, Neoplasms, Squamous Cell, Carcinoma
Interventions: 5-fluorouracil, Placebo, vehicle control; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Not listed
Enrollment: 954 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 13
States / cities: Palo Alto, California • San Diego, California • Denver, Colorado + 10 more

Conditions: Schizophrenia
Interventions: PF-06412562 3mg BID, PF-06412562 9mg BID, PF-06412562 45mg BID, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: Arcadia, California • Glendale, California • Baltimore, Maryland + 2 more

Conditions: Clostridium Difficile Infection
Interventions: SER-109, Placebo; Biological · Drug
Lead sponsor: Seres Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 51
States / cities: North Little Rock, Arkansas • Mather, California • Mountain View, California + 46 more

Conditions: Plaque Psoriasis
Interventions: Roflumilast foam 0.3%, Vehicle foam; Drug
Lead sponsor: Arcutis Biotherapeutics, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 31
States / cities: Rogers, Arkansas • Fremont, California • San Diego, California + 27 more

Conditions: RSV Infection
Interventions: RSV 6120/∆NS1, RSV 6120/F1/G2/∆NS1, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Months to 59 Months
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Schizophrenia
Interventions: Aticaprant, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 8
States / cities: Garden Grove, California • Atlanta, Georgia • Chicago, Illinois + 5 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: Saline Placebo (0.5mL injection), RSV F vaccine (0.5mL injection); Drug
Lead sponsor: Novavax; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 7
States / cities: Nampa, Idaho • Hutchinson, Kansas • Kansas City, Kansas + 4 more

Conditions: Sleep, Endometrial Neoplasms, Pain
Interventions: zolpidem, sugar pill; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Mepolizumab, Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 806 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 88
States / cities: Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 72 more

Conditions: Fracture
Interventions: Vitamin D3, Placebo; Drug · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 50 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Itepekimab SAR440340, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 1,234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 59
States / cities: Phoenix, Arizona • Fresno, California • Palm Springs, California + 49 more

Conditions: Arthroplasty
Interventions: Tapentadol IR (CG5503), Placebo, Oxycodone HCL IR; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 45
States / cities: Birmingham, Alabama • Mobile, Alabama • Sheffield, Alabama + 42 more

Conditions: Human Immunodeficiency Virus
Interventions: Baricitinib 2 MG Oral Tablet, Placebo; Drug
Lead sponsor: William Tyor; Other
Eligibility: 18 Years to 65 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Allergic Conjunctivitis
Interventions: Dexamethasone 0.1% ophthalmic suspension, Olopatadine hydrochloride 0.1% ophthalmic solution, Inactive ingredients, used as placebo; Drug · Other
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Psoriasis
Interventions: BMS-986165, Placebo for BMS-986165; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 268 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 16
States / cities: Irvine, California • San Diego, California • Ocala, Florida + 13 more

Conditions: Sprains and Strains
Interventions: Passive Positioning, High-Velocity, Low-Amplitude Stretch, Slow, Mobilization Stretch; Other
Lead sponsor: University of the Pacific; Other
Eligibility: 16 Years to 60 Years
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Stockton, California

Search by objective public record fields.

Study to Evaluate Coconut Oil for Alzheimer's Disease

JDS-HF3.0 Supplementation on Menopause Related Quality of Life Outcomes in Postmenopausal Women

Precision Pain Management - A Randomized Clinical Trial Assessing the Efficacy of Suzetrigine on Postoperative Analgesia Among Surgical Patients at Higher Risk for Persistent Postoperative Opioid Use (POU)

Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults

Mindfulness Intervention and Symptom Variability in Hearing

Theta Burst Stimulation for Refractory Depression in Autism Spectrum Disorder

Perioperative Methadone Use to Decrease Opioid Requirement in Pediatric Spinal Fusion Patients

Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma

CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial

A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia

ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection

Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis

Evaluating the Infectivity, Safety and Immunogenicity of Respiratory Syncytial Virus Vaccines, RSV 6120/∆NS1 and RSV 6120/F1/G2/∆NS1, in RSV-Seropositive Children and RSV-Seronegative Infants and Children

A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia

RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.

Sleep and Endometrial Cancer

Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

Optimal Vitamin D3 Supplementation Strategies for Acute Fracture Healing

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)

A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain After Hip Replacement Surgery Compared With Oxycodone and Placebo Followed by a Voluntary Open-Label Extension For Safety

Baricitinib for Reduction of HIV - CNS

Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis

Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis

Ankle Manual Therapy for Ankle Sprains